期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

氯吡格雷和阿司匹林在动脉粥样硬化血栓形成二级预防和高危患者一级预防中的作用 被引量：4

The Effect of Clopidogrel and Aspirin on the Secondary Prevention of Atherothrombosis and Primary Prevention in Patients with High Risk
原文传递
导出
摘要 动脉粥样硬化血栓形成直接危害着人们的健康和生命,目前大有在全球流行的趋势。如何及时发现动脉粥样硬化血栓形成高危患者,氯吡格雷在这些患者二级和一级预防中究竟有哪些作用都是值得研究的问题。正在进行的氯吡格雷用于高度动脉粥样硬化血栓形成危险和缺血的稳定性、处理及规避(CHARISMA)试验将对此进行有益探索。 Atherothrombosis directly threatens people＇s health and lives. Currently it has a tendency of global prevalence. How to identify the high-risk patients with atherothrombosis in time, and what roles on earth clopidogrel plays in patients＇ primary and secondary prevention are all the problems to be investigated. An ongoing project of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance （CHARISMA） trial will make beneficial exploration for it.
作者 苏克江 高宗恩
机构地区 解放军 胜利油田中心医院
出处 《国际脑血管病杂志》 2006年第3期210-215,共6页 International Journal of Cerebrovascular Diseases
关键词 氯吡格雷 阿司匹林 动脉粥样硬化血栓形成 卒中预防 危险因素 clopidogrel aspirin atherothrombosis stroke prevention risk factor
分类号 R543.5 [医药卫生—心血管疾病] R364.15 [医药卫生—病理学]
  • 相关文献

参考文献26

  • 1Bhatt DL,Topol E J,Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization,Management,et al.Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention:rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization,Management,and Avoidance (CHARISMA) trial.Am Heart J,2004,148:263-268.
  • 2Bhatt DL,Fox KA,Hacke W,et al.A global view of atherothrombosis:baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization,Management,and Avoidance (CHARISMA) trial.Am Heart,2005,150:401.
  • 3Expert Panel on Detection,Evaluation,and Treatment of High Blood Cholesterol in Adults.Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection,Evaluation,And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel Ⅲ).JAMA,2001,285:2486-2497.
  • 4Najarian RM,Sullivan LM,Kannel WB,et al.Metabolic syndrome compared with type 2 diabetes mellitus as a risk factor for stroke:The Framingham Offspring Study.Arch Intern Med,2006,166:106-111.
  • 5Narayan KM,Boyle JP,Thompson TJ,et al.Lifetime risk for diabetes mellitus in the United States.JAMA,2003,290:1884-1890.
  • 6Antithrombotic Trialists' Collaboration.Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death,myocardial infarction and stroke in high risk patients.BMJ,2002,324:71-86.
  • 7Sanmuganathan PS,Ghahramani P,Jackson PR,et al.Aspirin for primary prevention of coronary heart disease:safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials.Heart,2001,85:265-271.
  • 8U.S.Preventive Services Task Force.Aspirin for the primary prevention of cardiovascular events:recommendation and rationale.Ann Intern Med,2002,136:157-160.
  • 9Sacks FM,Pfeffer MA,Moye LA,et al.The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.Cholesterol and Recurrent Events Trial investigators.N Engl J Med,1996,335:1001-1009.
  • 10LaRosa JC,He J,Vupputuri S.Effect of statins on risk of coronary disease:a meta-analysis of randomized controlled trials.JAMA,1999,282:2340-2346.

同被引文献1641

引证文献4

二级引证文献8

国际脑血管病杂志
2006年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部